48-week outcomes following switch from AZT/3TC to FTC/TDF (TVD) vs. continuing on AZT/3TC: 48-week interim analysis of the RECOMB trial

Esteban Ribera(Hospital Terrassa), ML Álvarez(Gilead Sciences (Spain)), Vicente Estrada(Instituto de Salud Carlos III), Adrián Curran(Lexington City Schools), Rafael Rubio(Research Institute Hospital 12 de Octubre), Bonaventura Clotet(Universitat de Vic - Universitat Central de Catalunya), Juan Berenguer(Instituto de Salud Carlos III), Maria Larrouse(Hospital Clínic de Barcelona), Estebán Martínez(Instituto de Salud Carlos III), Jesús Sanz(Universidad Complutense de Madrid), Federico Pulido(Bellvitge University Hospital), Pedro Eitz Ferrer(Gilead Sciences (Spain)), Eugènia Negredo(Universitat de Vic - Universitat Central de Catalunya)
Journal of the International AIDS Society
January 1, 2008
10.1186/1758-2652-11-s1-p54
Cited by 2

Related Papers

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy
|JAMA|2016|1.4k
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
|The Lancet|2019|1k
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|728
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653
Pitavastatin to Prevent Cardiovascular Disease in HIV Infection
|New England Journal of Medicine|2023|476